- Home
- NPCE vs PRTA Comparison
NPCE vs PRTA Comparison
Compare NPCE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | PRTA |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.3M | 495.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NPCE | PRTA |
|---|---|---|
| Price | $15.14 | $9.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $18.00 | ★ $18.86 |
| AVG Volume (30 Days) | 196.0K | ★ 776.0K |
| Earning Date | 11-04-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $94,864,000.00 | $11,786,000.00 |
| Revenue This Year | $24.82 | N/A |
| Revenue Next Year | $0.77 | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $7.56 | $4.32 |
| 52 Week High | $18.98 | $16.67 |
Technical Indicators
Market Signals| Indicator | NPCE | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 39.77 |
| Support Level | $15.29 | $9.23 |
| Resistance Level | $16.33 | $9.88 |
| Average True Range (ATR) | 0.54 | 0.44 |
| MACD | -0.27 | -0.05 |
| Stochastic Oscillator | 5.77 | 5.94 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.